𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacokinetic comparison of sinemet and atamet (Generic carbidopa/levodopa): A single-dose study

✍ Scribed by Dr. R. Pahwa; J. Marjama; D. McGuire; K. Lyons; F. Zwiebel; P. Silverstein; R. Ward; W. C. Koller

Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
346 KB
Volume
11
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

We compared the pharmacokinetic and motor responses of Sinemet and Atamet (generic carbidopa/levodopa) in patients with Parkinson's disease. Thirty Parkinson's disease patients (10 previously untreated, 10 with early disease, and 10 with motor fluctuations/dyskinesia) participated in a single‐dose double‐blind study. Following administration of an equivalent oral dose of Sinemet and Atamet on two separate days, we compared the peak plasma concentration, time to peak plasma concentration, area under the curve, total motor score, tapping score, and walking time. The mean time to peak plasma concentration was 49 min with Sinemet and 47 min with Atamet, the mean peak plasma concentration was 1,273 ng/ml with Sinemet and 1,153 ng/ml with Atamet, and the mean area under the curve was 2,295 m̈g/ml/h with Sinemet and 2,330 m̈g/ml/h with Atamet. Similarly, there was no significant difference between total motor score, tapping score, of walking time. In this single‐dose study, there were no significant differences in pharmacokinetic and motor responses between Sinmet and Atamet.

📜 SIMILAR VOLUMES

Comparison of orally dissolving carbidop
Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial
✍ William G. Ondo; Lina Shinawi; Steven Moore 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 269 KB

## Abstract Levodopa use in fluctuating Parkinson's disease (PD) is complicated by an inconsistent and prolonged onset to clinical improvement. An orally dissolved carbidopa/levodopa (OD C/L) preparation (Parcopa UCB Pharma) is available in the United States. This offers potential advantages to sho

Pharmacokinetic analysis of sustained-re
Pharmacokinetic analysis of sustained-release dosage forms of theophylline in humans: Comparison of single and multiple dose studies
✍ Ziad Hussein; Meir Bialer; Michael Friedman; Itamar Raz 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 413 KB 👁 2 views

A pharmacokinetic analysis of two sustained-release dosage forms of theophylline (Theo-Dur@ and Theotrim@) was carried out following single and multiple dose administrations of the two formulations in five healthy subjects. Despite the prolonged absorption after administration of the two sustained-r

Lack of effect of liver disease on the p
Lack of effect of liver disease on the pharmacokinetics of acebutolol and diacetolol: A single dose study
✍ R. Zaman; D. B. Jack; M. R. Wilkins; M. J. Kendall 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 301 KB 👁 2 views

The pharmacokinetics of acebutolol and its major metabolite, diacetolol, following a single 400 mg oral dose, were investigated in patients with liver disease. No significant differences were found in any of the parameters measured.

End-of-dose akinesia after a single intr
End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double-blind study
✍ Nicolas Simon; Joëlle Micallef; Jean-Charles Reynier; Monique Lesourd; Tatiana W 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 1 views

## Abstract This randomized, double‐blind trial was designed to define the possible relationship between piribedil plasma concentrations and the decrease of the Unified Parkinson's Disease Rating Scale (UPDRS) motor score or the switch from __off__ to __on__ state after single intravenous infusion.